Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioreductive agents: a clinical update

M J Boyer1

  • 1Department of Medical Oncology, Royal Prince Alfred Hospital, NSW, Australia. mboyer@canc.rpa.cs.nsw.gov.au

Oncology Research
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.

British journal of cancer·2015
Same author

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.

British journal of cancer·2014
Same author

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.

British journal of cancer·2014
Same author

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

European journal of cancer (Oxford, England : 1990)·2013
Same author

Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.

Journal of clinical pathology·2013
Same journal

New Paradigm in Ocular Surface Squamous Neoplasia-Insights from a Case Report on the Use of Interferon in Treatment.

Oncology research·2026
Same journal

Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy.

Oncology research·2026
Same journal

Exploring the Role of CD44 in the Progression and Invasion of Chondrosarcoma.

Oncology research·2026
Same journal

Retraction: Long Noncoding RNA Taurine-Upregulated Gene 1 Promotes Cell Proliferation and Invasion in Gastric Cancer via Negatively Modulating miRNA-145-5p.

Oncology research·2026
Same journal

Retraction: Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.

Oncology research·2026
Same journal

Targeting Dynamin-Related Protein 1 and Glucose Metabolism Reverses Acquired Resistance to Sorafenib in Liver Cancer.

Oncology research·2026
See all related articles

Bioreductive agents exploit tumor hypoxia for targeted cancer cell killing. While mitomycin C and EO9 show limited success, tirapazamine is a promising new agent undergoing extensive clinical trials.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Bioreductive agents require reduction to active cytotoxic forms.
  • Tumor hypoxia presents a target for selective cancer therapy.
  • Mitomycin C is the only clinically used bioreductive agent, with potential activity linked to its bioreductive properties.

Purpose of the Study:

  • To review the role and potential of bioreductive agents in cancer treatment.
  • To evaluate the clinical progress of EO9 and tirapazamine.
  • To assess the therapeutic implications of tumor hypoxia in drug development.

Main Methods:

  • Review of clinical trial data for bioreductive agents.
  • Analysis of drug mechanisms of action, focusing on bioreduction.

Related Experiment Videos

  • Evaluation of tumor hypoxia as a therapeutic target.

    • Main Results:

    • Mitomycin C's efficacy may be partly due to bioreductive properties, despite non-specific cytotoxicity.
    • Early clinical trials of EO9 did not demonstrate significant antitumor activity.
    • Tirapazamine shows encouraging early results in various clinical trial settings.

    Conclusions:

    • Bioreductive agents hold promise for tumor-specific cancer therapy.
    • Further randomized trials are necessary to confirm the efficacy of tirapazamine.
    • Targeting tumor hypoxia remains a key strategy in developing novel cancer treatments.